[Summary] With the corporate vision of "professional, dedicated and devoted to t
Jiangsu Kaiyuan Pharmaceutical Co., Ltd. was founded in 2008 and is headquartered in Jiangsu Life Science Park, Qixia High-tech Zone, Nanjing City, Jiangsu Province. It currently has more than 500 employees and 7 wholly-owned subsidiaries, and is a comprehensive international biopharmaceutical enterprise integrating biopharmaceutical R&D, production and trade. Its main products cover pharmaceutical intermediates, APIs, finished drugs and medical devices. It engages in R&D activities such as generic drug consistency evaluation, improved new drugs and innovative drug R&D, and MAH, and owns several CDMO production bases for pharmaceutical intermediates, APIs and finished drugs. The company takes industry as support, R&D to drive trade, and trade to promote development. Adhering to a customer-centric approach and oriented by enhancing corporate value, it strives to provide customers with high-quality, efficient services and technical support, and has gained broader development space by virtue of high quality, excellent service and a good brand. It enjoys high visibility and a good reputation in the international and domestic biopharmaceutical and healthcare fields. The headquarters, Kaiyuan Pharmaceutical, is committed to the import and export trade of pharmaceutical and healthcare products. Its traded products include pharmaceutical intermediates, APIs, finished drugs, medical devices, etc., and are sold to more than 120 countries or regions such as the United States, Europe, Russia, India, the Middle East, Africa, Asia-Pacific and South America. It has formed long-term stable cooperative relations with more than 5,000 customers. The company's annual export value exceeds US$200 million and annual sales exceed RMB 1.5 billion. It has been awarded the title of "Top Ten Western and Finished Drug Export Enterprises" by the China Chamber of Commerce for Import and Export of Medicines and Health Products for 9 consecutive years, and has been ranked among the "Top 100 Chinese Pharmaceutical Internationalization Enterprises" for 6 consecutive years. In 2017, the company was successfully elected as Vice Chairman Unit of the China Chamber of Commerce for Import and Export of Medicines and Health Products. The core subsidiary Kaiyuan Pharmaceutical Industry is committed to the field of drug R&D, with an R&D center covering an area of 4,000 square meters and a professional core technical team of more than 100 people, specializing in R&D activities such as chemical small-molecule innovative drug development, generic drug consistency evaluation, CRO and MAH. It has established industry-university-research cooperation relations with many institutions and research units such as China Pharmaceutical University and Nanjing University of Chinese Medicine, and has reached pharmaceutical R&D strategic cooperation with well-known domestic pharmaceutical enterprises such as Sinopharm Group, Guangzhou Pharmaceutical Group, Guobang Pharmaceutical Group and Dingtai Pharmaceutical Research Group. Beijia Pharmaceutical is located in "China Medical City" in Taizhou, Jiangsu, and is one of Kaiyuan Pharmaceutical's formulation production bases. Its main business includes export entrusted production, MAH entrusted production, etc. It has GMP-compliant production workshops for tablets and hard capsules, holds production approvals for three drugs of two products, namely Cefadroxil Capsules and Chloramphenicol Capsules, holds the Drug Production License for capsules, tablets, oral solutions and granules, and has completed six drug production lines with an annual capacity of 1 billion capsules/tablets and 30 million bottles of oral solutions. It can simultaneously meet large-batch entrusted drug processing and production for domestic and foreign customers. Kaiyuan Pharmaceutical is located in Suzhou Economic Development Zone, Anhui, covering an area of 300 mu, and is one of Kaiyuan Pharmaceutical's production bases. The total investment is RMB 1 billion. The Phase I construction project implements projects such as "annual production of 600 tons of fosfomycin levoamine salt, 250 tons of fosfomycin calcium, 50 tons of fosfomycin sodium, 50 tons of fosfomycin trometamol and 1,000 kg of sucrose octasulfate salt". After the Phase I project is put into production, the annual output value will be RMB 500 million, and the Phase II project is under preparation. Due to the different work contents and nature of each subsidiary, there are slight differences in various benefits and working hours. For details, please consult the person in charge of each subsidiary.
What does Jiangsu Kaiyuan Pharmaceutical Co., Ltd. require? Who is Kaiyuan Pharmaceutical hiring? Kaiyuan Pharmaceutical recruitment: 生物/制药/化工/环保类占比最多占35.1%,其次是经营管理类占32.4%. What education can get in at Kaiyuan Pharmaceutical? 本科占比最多占63.5%,其次是大专占27%. High education required at Kaiyuan Pharmaceutical? 硕士占5.4%. Work experience required at Kaiyuan Pharmaceutical? 3-5年占比最多占32.4%,其次是不限占28.4%. Where are the job locations at Kaiyuan Pharmaceutical? 南京占比最多占78.4%,其次是宿州占21.6%. Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows